Patients w/ activated renin-angiotensin system who are receiving angiotensin receptor blockers; K level must be monitored when there is a concomitant use w/ K-containing products; unilateral or bilateral renal artery stenosis; hepatic impairment or biliary obstructive disorders; serious CHF; aortic or mitral stenosis or obstructive hypertrophic cardiomyopathy. Discontinue if angioedema develops. Hyperkalaemia. Lactation. Childn <18 yr.
Simvastatin, CYP3A4 inducers & inhibitors, K supplements, K-sparing diuretics, K-containing salt substitutes or other drugs that may increase K levels (heparin), NSAIDs, uptake transporter inhibitors (rifampin, ciclosporin).